ライフサイエンスコーパス: scintillation proximity assay

1 ified biochemically with a cytosol-dependent scintillation proximity assay.

2 y were determined using this FP method and a scintillation proximity assay.

3 rsible loss of ligand binding as assessed by scintillation proximity assay.

4 rs of human DNA topoisomerase I based on the scintillation proximity assay.

5 (3)H]troglitazone, a PPARgamma agonist, in a scintillation proximity assay.

6 ration calorimetry, equilibrium dialysis and scintillation proximity assays.

7 nding and peptide-myristoylation activity in scintillation proximity assays.

8 e use of AMP-PCP coupled with the use of the scintillation proximity assay allows this characterizati

9 high-throughput screening, are described: a scintillation proximity assay and a time-resolved fluore

10 We have developed a cell-free and scintillation-proximity assay-based screen to search for

11 cts by immobilization on streptavidin-coated scintillation proximity assay beads.

12 rmat described is called an aaRS competitive scintillation proximity assay (cSPA).

13 Scintillation proximity assays designed to look at the b

14 method described here is the first reported scintillation proximity assay for a peroxisome prolifera

15 A scintillation proximity assay for measurement of 3H-radi

16 A scintillation proximity assay for peroxisome proliferato

17 (50) values obtained by FP binding assay and scintillation proximity assay for the clinically used PP

18 The molecule exhibits activity in a scintillation-proximity assay for the inhibition of the

19 assay for acetyl CoA carboxylase (ACC) in a scintillation proximity assay format suitable for high-t

20 To our knowledge this ACC/FAS coupled scintillation proximity assay is the only assay format t

21 PAR ligands obtained in FP binding assay and scintillation proximity assay or gel filtration binding

22 Identified "hits" were then confirmed in a scintillation proximity assay (SPA) and a DEAE membrane-

23 neous proximity assays for tyrosine kinases, scintillation proximity assay (SPA) and homogeneous time

24 e obtained from the conventional assay using scintillation proximity assay (SPA) beads and a scintill

25 By using wheat germ agglutinin (WGA)-coated scintillation proximity assay (SPA) beads to capture 125

26 mer was immobilized onto streptavidin-coated scintillation proximity assay (SPA) beads, and after add

27 We describe the first validated scintillation proximity assay (SPA) binding method for q

28 Here we report the development of a coupled scintillation proximity assay (SPA) for 3 KDMs: KDM1A (L

29 A homogeneous scintillation proximity assay (SPA) for detection of RNA

30 hput, we have developed a novel, homogeneous scintillation proximity assay (SPA) for DGAT.

31 Here, by adapting the scintillation proximity assay (SPA) for direct determina

32 We have developed a novel 96-well plate scintillation proximity assay (SPA) for measuring small

33 A simple, high-throughput scintillation proximity assay (SPA) for parathyroid horm

34 using biotinylated NAD, we have developed a scintillation proximity assay (SPA) for PARP.

35 Here we report a 96-well homogeneous scintillation proximity assay (SPA) for the study of Dna

36 usly identified, with a pIC(50) >= 5.0, in a scintillation proximity assay (SPA) HTS at a lower hit r

37 stone deacetylase assay that is based on the scintillation proximity assay (SPA) principle.

38 fatty acid amide hydrolase (FAAH) using the scintillation proximity assay (SPA) technology is descri

39 , and homogeneous binding assay based on the scintillation proximity assay (SPA) technology that prov

40 o previously reported procedures: the use of scintillation proximity assay (SPA) technology to measur

41 (RPA) with the quantification advantages of scintillation proximity assay (SPA) technology.

42 H2 domain with a phosphopeptide ligand using scintillation proximity assay (SPA) technology.

43 We have developed a quantitative scintillation proximity assay (SPA) that reproduces the

44 We have adapted and optimized a scintillation proximity assay (SPA) to replace the more

45 A scintillation proximity assay (SPA) using 33phosphorous

46 A scintillation proximity assay (SPA) was developed to det

47 tosaminyltransferase (GalNAc-transferase) by scintillation proximity assay (SPA) was developed.

48 We have developed a scintillation proximity assay (SPA) where use of biotiny

49 de triphosphatase activity was measured in a scintillation proximity assay (SPA)-based high-throughpu

50 metal ion affinity chromatography (IMAC) and scintillation proximity assay (SPA).

51 ter-binding format or by a novel homogeneous scintillation proximity assay (SPA).

52 es than on DNA-core-trimmed nucleosomes in a scintillation proximity assay (SPA).

53 In combination with the scintillation proximity assay (SPA[trade]), this allows

54 We developed scintillation proximity assays (SPA) to discover compoun

55 d the purified DII S1-S4 protein to create a scintillation proximity assay suitable for high-throughp

56 roduct is then directly quantified using the scintillation proximity assay technology: binding of the

57 distinct inhibitory profile, we developed a scintillation proximity assay that permits analysis of r

58 The screen uses a scintillation proximity assay to identify compounds that

59 The soluble receptor was used in a scintillation proximity assay to identify two chemical c

60 We now describe a scintillation proximity assay to measure soluble inosito

61 try of the targeting process, we developed a scintillation proximity assay to study the stepwise asso

62 Using the antibody-capture [(35)S]GTPgammaS scintillation proximity assay, we demonstrated for the f

63 format for the detection of inhibition is a scintillation proximity assay which is robust and reprod